Protocol Ledger

NCT03585270 · Phase III · COMPLETED

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

Interventional Phase III clinical trial protocol NCT03585270 sponsored by Idorsia Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-03 Enrollment: 409 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03585270
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)409 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03585270
Protocol FieldVerified Registry Value
NCT IdentifierNCT03585270
Consolidated Lead SponsorIdorsia Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment409 participants (ACTUAL)
Registered Start Date2019-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI